Advertisement

help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hoekstra, R.
Right arrow Articles by Verweij, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hoekstra, R.
Right arrow Articles by Verweij, J.
The Oncologist, Vol. 6, No. 5, 415-427, October 2001
© 2001 AlphaMed Press

Matrix Metalloproteinase Inhibitors: Current Developments and Future Perspectives

R. Hoekstra, F.A.L.M. Eskens, J. Verweij

Department of Medical Oncology, Rotterdam Cancer Institute (Daniel den Hoed Kliniek) and University Hospital, Rotterdam, The Netherlands

Correspondence: Ronald Hoekstra, M.D., Department of Medical Oncology, University Hospital Rotterdam, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands. Fax: 31-10-463-4627; e-mail: hoekstra{at}oncd.azr.nl

Malignant tumors are characterized by invasive growth and metastasis. To facilitate this invasive behavior, the enzymatic breakdown of the extracellular matrix (ECM) is a prerequisite. Many human tumors are characterized by locally increased concentrations of matrix metalloproteinases (MMPs), enzymes that are able to degrade this ECM. A vast number of matrix metalloproteinase inhibitors (MMPIs) have been developed in recent years and after extensive preclinical testing, the results of the first clinical studies with several of these compounds have recently been presented. In this review we will describe some of the basic concepts of the degradation of the ECM, with special emphasis on the role of MMPs in the progression of cancer. Furthermore we will review the results of preclinical and clinical studies with MMPIs and discuss their future perspective.

Key Words. Matrix metalloproteinases • Matrix metalloproteinase inhibitors • Cancer • Clinical studies




This article has been cited by other articles:


Home page
Cardiovasc ResHome page
J. P.G. Sluijter, D. P.V. de Kleijn, and G. Pasterkamp
Vascular remodeling and protease inhibition-bench to bedside
Cardiovasc Res, February 15, 2006; 69(3): 595 - 603.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
D. Vanhoutte, M. Schellings, Y. Pinto, and S. Heymans
Relevance of matrix metalloproteinases and their inhibitors after myocardial infarction: A temporal and spatial window
Cardiovasc Res, February 15, 2006; 69(3): 604 - 613.
[Abstract] [Full Text] [PDF]


Home page
Mayo Clin Proc.Home page
E. C. Miner and W. L. Miller
A Look Between the Cardiomyocytes: The Extracellular Matrix in Heart Failure
Mayo Clin. Proc., January 1, 2006; 81(1): 71 - 76.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
C. Guignabert, L. Taysse, J.-H. Calvet, E. Planus, S. Delamanche, S. Galiacy, and M.-P. d'Ortho
Effect of doxycycline on sulfur mustard-induced respiratory lesions in guinea pigs
Am J Physiol Lung Cell Mol Physiol, July 1, 2005; 289(1): L67 - L74.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
M. KJAeR
Role of Extracellular Matrix in Adaptation of Tendon and Skeletal Muscle to Mechanical Loading
Physiol Rev, April 1, 2004; 84(2): 649 - 698.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
W. M. Yarbrough, R. Mukherjee, G. P. Escobar, J. T. Mingoia, J. A. Sample, J. W. Hendrick, K. B. Dowdy, J. E. McLean, A. S. Lowry, T. P. O'Neill, et al.
Selective Targeting and Timing of Matrix Metalloproteinase Inhibition in Post-Myocardial Infarction Remodeling
Circulation, October 7, 2003; 108(14): 1753 - 1759.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
G. van der Pluijm, M. Deckers, B. Sijmons, H. de Groot, J. Bird, R. Wills, S. Papapoulos, A. Baxter, and C. Lowik
In Vitro and in Vivo Endochondral Bone Formation Models Allow Identification of Anti-Angiogenic Compounds
Am. J. Pathol., July 1, 2003; 163(1): 157 - 163.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
B.-K. Choi, H. J. Lee, J. H. Kang, G. J. Jeong, C. K. Min, and Y.-J. Yoo
Induction of Osteoclastogenesis and Matrix Metalloproteinase Expression by the Lipooligosaccharide of Treponema denticola
Infect. Immun., January 1, 2003; 71(1): 226 - 233.
[Abstract] [Full Text] [PDF]




HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2001 by AlphaMed Press.
Advertisement